Logo image of NRXS

NEURAXIS INC (NRXS) Stock Fundamental Analysis

USA - NYSEARCA:NRXS - US64134X2018 - Common Stock

2.41 USD
-0.15 (-5.86%)
Last: 11/11/2025, 8:04:00 PM
2.38 USD
-0.03 (-1.24%)
After Hours: 11/11/2025, 8:04:00 PM
Fundamental Rating

3

Taking everything into account, NRXS scores 3 out of 10 in our fundamental rating. NRXS was compared to 189 industry peers in the Health Care Equipment & Supplies industry. While NRXS seems to be doing ok healthwise, there are quite some concerns on its profitability. NRXS is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year NRXS has reported negative net income.
NRXS had a negative operating cash flow in the past year.
NRXS had negative earnings in each of the past 5 years.
In the past 5 years NRXS always reported negative operating cash flow.
NRXS Yearly Net Income VS EBIT VS OCF VS FCFNRXS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -5M -10M

1.2 Ratios

NRXS has a worse Return On Assets (-110.11%) than 78.84% of its industry peers.
Looking at the Return On Equity, with a value of -183.49%, NRXS is doing worse than 70.37% of the companies in the same industry.
Industry RankSector Rank
ROA -110.11%
ROE -183.49%
ROIC N/A
ROA(3y)-1140.93%
ROA(5y)-815%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NRXS Yearly ROA, ROE, ROICNRXS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 1K -1K -2K

1.3 Margins

Looking at the Gross Margin, with a value of 84.82%, NRXS belongs to the top of the industry, outperforming 94.18% of the companies in the same industry.
NRXS's Gross Margin has improved in the last couple of years.
NRXS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 84.82%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.51%
GM growth 5YN/A
NRXS Yearly Profit, Operating, Gross MarginsNRXS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 -200 -400

More info and screens

6

2. Health

2.1 Basic Checks

NRXS does not have a ROIC to compare to the WACC, probably because it is not profitable.
NRXS has more shares outstanding than it did 1 year ago.
The debt/assets ratio for NRXS has been reduced compared to a year ago.
NRXS Yearly Shares OutstandingNRXS Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2M 4M 6M
NRXS Yearly Total Debt VS Total AssetsNRXS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 1M 2M 3M 4M

2.2 Solvency

NRXS has an Altman-Z score of -8.80. This is a bad value and indicates that NRXS is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -8.80, NRXS is not doing good in the industry: 75.66% of the companies in the same industry are doing better.
There is no outstanding debt for NRXS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -8.8
ROIC/WACCN/A
WACC8.83%
NRXS Yearly LT Debt VS Equity VS FCFNRXS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 2M -2M -4M -6M

2.3 Liquidity

NRXS has a Current Ratio of 2.82. This indicates that NRXS is financially healthy and has no problem in meeting its short term obligations.
NRXS has a Current ratio of 2.82. This is comparable to the rest of the industry: NRXS outperforms 56.08% of its industry peers.
NRXS has a Quick Ratio of 2.76. This indicates that NRXS is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of NRXS (2.76) is better than 66.14% of its industry peers.
Industry RankSector Rank
Current Ratio 2.82
Quick Ratio 2.76
NRXS Yearly Current Assets VS Current LiabilitesNRXS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2M 4M 6M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 66.66% over the past year.
Looking at the last year, NRXS shows a very strong growth in Revenue. The Revenue has grown by 41.77%.
NRXS shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -0.42% yearly.
EPS 1Y (TTM)66.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%47.62%
Revenue 1Y (TTM)41.77%
Revenue growth 3Y-0.42%
Revenue growth 5YN/A
Sales Q2Q%46.57%

3.2 Future

NRXS is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -37.51% yearly.
The Revenue is expected to grow by 13.42% on average over the next years. This is quite good.
EPS Next Y-785%
EPS Next 2Y-101.25%
EPS Next 3Y-37.51%
EPS Next 5YN/A
Revenue Next Year-65.93%
Revenue Next 2Y-11.39%
Revenue Next 3Y13.42%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
NRXS Yearly Revenue VS EstimatesNRXS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 5M 10M 15M
NRXS Yearly EPS VS EstimatesNRXS Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 -0.2 -0.4 -0.6 -0.8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

NRXS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year NRXS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NRXS Price Earnings VS Forward Price EarningsNRXS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NRXS Per share dataNRXS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1

4.3 Compensation for Growth

A cheap valuation may be justified as NRXS's earnings are expected to decrease with -37.51% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-101.25%
EPS Next 3Y-37.51%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NRXS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEURAXIS INC

NYSEARCA:NRXS (11/11/2025, 8:04:00 PM)

After market: 2.38 -0.03 (-1.24%)

2.41

-0.15 (-5.86%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-12 2025-08-12/bmo
Earnings (Next)11-11 2025-11-11/bmo
Inst Owners5.54%
Inst Owner Change9.21%
Ins Owners20.39%
Ins Owner Change-37.65%
Market Cap23.79M
Revenue(TTM)3.22M
Net Income(TTM)-7.80M
Analysts82.5
Price Target5.99 (148.55%)
Short Float %0.24%
Short Ratio0.04
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-20.01%
Min EPS beat(2)-34.8%
Max EPS beat(2)-5.21%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-55.37%
Min Revenue beat(2)-99.88%
Max Revenue beat(2)-10.86%
Revenue beat(4)0
Avg Revenue beat(4)-67.3%
Min Revenue beat(4)-99.88%
Max Revenue beat(4)-10.86%
Revenue beat(8)0
Avg Revenue beat(8)-69.11%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-6%
EPS NQ rev (1m)0%
EPS NQ rev (3m)8.11%
EPS NY rev (1m)0%
EPS NY rev (3m)9.69%
Revenue NQ rev (1m)-9.09%
Revenue NQ rev (3m)-16.67%
Revenue NY rev (1m)-7.03%
Revenue NY rev (3m)-12.89%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.39
P/FCF N/A
P/OCF N/A
P/B 5.59
P/tB 5.72
EV/EBITDA N/A
EPS(TTM)-1.01
EYN/A
EPS(NY)-0.41
Fwd EYN/A
FCF(TTM)-0.63
FCFYN/A
OCF(TTM)-0.63
OCFYN/A
SpS0.33
BVpS0.43
TBVpS0.42
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -110.11%
ROE -183.49%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 84.82%
FCFM N/A
ROA(3y)-1140.93%
ROA(5y)-815%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.51%
GM growth 5YN/A
F-Score4
Asset Turnover0.45
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 84.14%
Cap/Sales 0.92%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.82
Quick Ratio 2.76
Altman-Z -8.8
F-Score4
WACC8.83%
ROIC/WACCN/A
Cap/Depr(3y)133.32%
Cap/Depr(5y)94.99%
Cap/Sales(3y)2.06%
Cap/Sales(5y)1.55%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)66.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%47.62%
EPS Next Y-785%
EPS Next 2Y-101.25%
EPS Next 3Y-37.51%
EPS Next 5YN/A
Revenue 1Y (TTM)41.77%
Revenue growth 3Y-0.42%
Revenue growth 5YN/A
Sales Q2Q%46.57%
Revenue Next Year-65.93%
Revenue Next 2Y-11.39%
Revenue Next 3Y13.42%
Revenue Next 5YN/A
EBIT growth 1Y17.87%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-920.73%
EBIT Next 3Y-60.66%
EBIT Next 5YN/A
FCF growth 1Y-160.49%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-161.44%
OCF growth 3YN/A
OCF growth 5YN/A

NEURAXIS INC / NRXS FAQ

What is the fundamental rating for NRXS stock?

ChartMill assigns a fundamental rating of 3 / 10 to NRXS.


What is the valuation status for NRXS stock?

ChartMill assigns a valuation rating of 0 / 10 to NEURAXIS INC (NRXS). This can be considered as Overvalued.


What is the profitability of NRXS stock?

NEURAXIS INC (NRXS) has a profitability rating of 1 / 10.